Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Pazdur

Showing results (71-80 of 468) with videos related to

Pageof 47
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2019
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Steven J Lemery, Patricia Keegan, et al.
Nature Reviews. Drug Discovery|May 23, 2015
Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?Sean Khozin, Ke Liu, Jonathan P Jarow, et al.
The Oncologist|December 15, 2010
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)Martin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|March 5, 2010
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumorsMartin H Cohen, Patricia Cortazar, Robert Justice, et al.
Oncology (Williston Park, N.Y.)|January 2, 2010
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraAndrew Dmytrijuk, Kathy Robie-Suh, Dwaine Rieves, et al.
The Oncologist|January 12, 2010
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaJeff Summers, Martin H Cohen, Patricia Keegan, et al.
Nature Clinical Practice. Urology|December 4, 2008
Expediting the availability of drugs for US patients with cancerAnn T Farrell, Richard Pazdur, Andrew C von Eschenbach
The Lancet. Oncology|April 17, 2022
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpointNicholas C Richardson, Yvette Kasamon, Richard Pazdur, et al.
Journal of Geriatric Oncology|December 27, 2016
Enrollment of older adults on oncology trials: An FDA perspectiveHarpreet Singh, Julia A Beaver, Geoffrey Kim, et al.
The Oncologist|July 3, 2007
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
Pageof 47

Showing results (71-80 of 468) with videos related to

Sort By:
Pageof 47
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2019
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid TumorsLeigh Marcus, Steven J Lemery, Patricia Keegan, et al.
Nature Reviews. Drug Discovery|May 23, 2015
Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?Sean Khozin, Ke Liu, Jonathan P Jarow, et al.
The Oncologist|December 15, 2010
Approval summary: pemetrexed maintenance therapy of advanced/metastatic nonsquamous, non-small cell lung cancer (NSCLC)Martin H Cohen, Patricia Cortazar, Robert Justice, et al.
The Oncologist|March 5, 2010
Approval summary: imatinib mesylate in the adjuvant treatment of malignant gastrointestinal stromal tumorsMartin H Cohen, Patricia Cortazar, Robert Justice, et al.
Oncology (Williston Park, N.Y.)|January 2, 2010
Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpuraAndrew Dmytrijuk, Kathy Robie-Suh, Dwaine Rieves, et al.
The Oncologist|January 12, 2010
FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinomaJeff Summers, Martin H Cohen, Patricia Keegan, et al.
Nature Clinical Practice. Urology|December 4, 2008
Expediting the availability of drugs for US patients with cancerAnn T Farrell, Richard Pazdur, Andrew C von Eschenbach
The Lancet. Oncology|April 17, 2022
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpointNicholas C Richardson, Yvette Kasamon, Richard Pazdur, et al.
Journal of Geriatric Oncology|December 27, 2016
Enrollment of older adults on oncology trials: An FDA perspectiveHarpreet Singh, Julia A Beaver, Geoffrey Kim, et al.
The Oncologist|July 3, 2007
FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerMartin H Cohen, Joe Gootenberg, Patricia Keegan, et al.
Pageof 47